Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Amarin Corporation plc is a biopharmaceutical company focused on the development and commercialization of prescription therapies for cardiovascular disease. The company operates within the pharmaceutical and biotechnology industries, with its business centered on lipid science and cardiovascular risk reduction. Amarin’s primary product and revenue driver is VASCEPA, a prescription omega-3 fatty acid–based therapy approved to reduce cardiovascular risk in certain patient populations.
The company’s key customer segments include cardiologists, primary care physicians, hospitals, and healthcare systems, with end users being patients at elevated risk of cardiovascular events. Amarin’s strategic positioning is based on clinical outcomes data demonstrating cardiovascular risk reduction beyond lipid lowering, which differentiates VASCEPA from dietary supplements and generic omega-3 products. Amarin was founded in 1993 and evolved from a development-stage biotechnology firm into a commercial-stage pharmaceutical company following U.S. regulatory approval and subsequent international market expansion of VASCEPA.
Business Operations
Amarin generates revenue primarily through the sale of VASCEPA in the United States and select international markets. The company’s operations are organized around a single commercial product, with activities spanning regulatory affairs, clinical development, medical affairs, marketing, and sales. Manufacturing is conducted through third-party contract manufacturers, while distribution is handled through established pharmaceutical supply chains.
Internationally, Amarin has pursued commercialization through a mix of direct operations and partnerships, including licensing and distribution agreements in parts of Europe, Asia, and the Middle East. The company controls intellectual property related to formulation, clinical use, and manufacturing processes for VASCEPA, although certain U.S. patents have faced legal challenges, influencing competitive dynamics in the domestic market.
Strategic Position & Investments
Amarin’s strategic direction emphasizes maximizing the global value of VASCEPA through geographic expansion, lifecycle management, and evidence generation supporting cardiovascular outcomes. Growth initiatives have included regulatory filings and launches in multiple international markets, as well as efforts to secure reimbursement and guideline inclusion outside the United States.
The company has historically invested heavily in clinical research, including large-scale cardiovascular outcomes trials that underpin its product differentiation. Amarin has not maintained a broad portfolio of subsidiaries or diversified product lines, and its investment strategy has remained focused on cardiovascular disease rather than expansion into unrelated therapeutic areas. Data inconclusive based on available public sources regarding any near-term transformative acquisitions or entry into materially new therapeutic sectors.
Geographic Footprint
Amarin is headquartered in Ireland, with principal executive offices and commercial operations in the United States. The U.S. market has historically represented the majority of revenue, supported by a dedicated sales force and established relationships with healthcare providers and payers.
Beyond the United States, Amarin has built a presence across Europe, including markets such as the United Kingdom, Germany, and Nordic countries, as well as selected countries in Asia-Pacific and other international regions through partners. The company’s global footprint reflects a strategy of targeting developed cardiovascular markets with established regulatory and reimbursement frameworks.
Leadership & Governance
Amarin is led by an executive team with experience in pharmaceuticals, cardiovascular medicine, and global commercialization. The leadership’s stated strategic vision centers on advancing science-based therapies that address unmet needs in cardiovascular risk reduction while driving long-term shareholder value through disciplined capital allocation.
Key members of Amarin’s leadership include:
- Aaron Berg – President and Chief Executive Officer
- Lyle D. Holman – Chief Financial Officer
- Rafik Bishay – Senior Vice President, Research and Development
- William D. Sibold – Executive Chairman of the Board
- Christine A. D’Elia – General Counsel and Corporate Secretary